Eli Lilly and Company (TSX:LLY)

Market Cap	1.30T
Revenue (ttm)	82.77B
Net Income (ttm)	25.65B
Shares Out	n/a
EPS (ttm)	28.47
PE Ratio	50.78
Forward PE	33.71
Dividend	n/a
Ex-Dividend Date	n/a

Volume	46,371
Average Volume	49,750
Open	37.64
Previous Close	37.85
Day's Range	37.64 - 39.16
52-Week Range	22.85 - 40.49
Beta	n/a
RSI	57.86
Earnings Date	Feb 6, 2026

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Pharmaceutical Preparations
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: LLY

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD